Eaton Vance Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.08B | Sell |
3,333,022
-175,598
| -5% | -$55.6M | 1.6% | 5 |
|
|
2022
Q2 | $1.14B | Sell |
3,508,620
-148,966
| -4% | -$44.7M | 1.6% | 6 |
|
|
2022
Q1 | $1.05B | Buy |
3,657,586
+91,899
| +3% | +$23.7M | 1.21% | 8 |
|
|
2021
Q4 | $985M | Buy |
3,565,687
+88,793
| +3% | +$22.5M | 1.2% | 11 |
|
|
2021
Q3 | $800M | Buy |
3,476,894
+142,561
| +4% | +$35.2M | 1.11% | 12 |
|
|
2021
Q2 | $765M | Buy |
3,334,333
+59,726
| +2% | +$12M | 1.03% | 13 |
|
|
2021
Q1 | $612M | Buy |
3,274,607
+58,196
| +2% | +$11.4M | 0.91% | 15 |
|
|
2020
Q4 | $543M | Buy |
3,216,411
+68,354
| +2% | +$10.2M | 0.85% | 17 |
|
|
2020
Q3 | $466M | Buy |
3,148,057
+67,044
| +2% | +$10.4M | 0.86% | 19 |
|
|
2020
Q2 | $506M | Sell |
3,081,013
-206,832
| -6% | -$31.7M | 1.03% | 14 |
|
|
2020
Q1 | $456M | Buy |
3,287,845
+128,154
| +4% | +$17.6M | 1.11% | 15 |
|
|
2019
Q4 | $415M | Buy |
3,159,691
+108,966
| +4% | +$12.6M | 0.81% | 25 |
|
|
2019
Q3 | $341M | Buy |
3,050,725
+5,269
| +0.2% | +$587K | 0.73% | 30 |
|
|
2019
Q2 | $337M | Buy |
3,045,456
+73,563
| +2% | +$8.66M | 0.74% | 26 |
|
|
2019
Q1 | $386M | Sell |
2,971,893
-90,623
| -3% | -$11M | 0.89% | 23 |
|
|
2018
Q4 | $354M | Sell |
3,062,516
-125,904
| -4% | -$14.1M | 0.92% | 23 |
|
|
2018
Q3 | $342M | Buy |
3,188,420
+17,848
| +0.6% | +$1.78M | 0.76% | 24 |
|
|
2018
Q2 | $271M | Sell |
3,170,572
-4,196,346
| -57% | -$345M | 0.64% | 31 |
|
|
2018
Q1 | $570M | Buy |
7,366,918
+3,301,969
| +81% | +$266M | 0.71% | 31 |
|
|
2017
Q4 | $343M | Sell |
4,064,949
-82,451
| -2% | -$7.02M | 0.83% | 25 |
|
|
2017
Q3 | $355M | Sell |
4,147,400
-1,254,710
| -23% | -$103M | 0.92% | 18 |
|
|
2017
Q2 | $445M | Buy |
5,402,110
+378,166
| +8% | +$30.9M | 1.17% | 12 |
|
|
2017
Q1 | $423M | Sell |
5,023,944
-350,849
| -7% | -$28.1M | 1.13% | 13 |
|
|
2016
Q4 | $395M | Buy |
5,374,793
+96,159
| +2% | +$7.16M | 1.11% | 15 |
|
|
2016
Q3 | $424M | Sell |
5,278,634
-219,893
| -4% | -$17.6M | 1.22% | 15 |
|
|
2016
Q2 | $433M | Buy |
5,498,527
+2,307,920
| +72% | +$174M | 1.26% | 14 |
|
|
2016
Q1 | $230M | Buy |
3,190,607
+301,431
| +10% | +$22.8M | 0.71% | 37 |
|
|
2015
Q4 | $243M | Buy |
2,889,176
+99,792
| +4% | +$8.28M | 0.72% | 38 |
|
|
2015
Q3 | $233M | Sell |
2,789,384
-685,543
| -20% | -$57.9M | 0.72% | 35 |
|
|
2015
Q2 | $290M | Sell |
3,474,927
-1,274,217
| -27% | -$97.1M | 0.89% | 26 |
|
|
2015
Q1 | $345M | Sell |
4,749,144
-250,178
| -5% | -$17.8M | 1.04% | 20 |
|
|
2014
Q4 | $345M | Buy |
4,999,322
+268,234
| +6% | +$18.1M | 1.02% | 24 |
|
|
2014
Q3 | $307M | Buy |
4,731,088
+3,502,529
| +285% | +$222M | 0.91% | 29 |
|
|
2014
Q2 | $76.4M | Buy |
1,228,559
+48,100
| +4% | +$2.87M | 0.23% | 120 |
|
|
2014
Q1 | $69.5M | Sell |
1,180,459
-3,270
| -0.3% | -$182K | 0.2% | 124 |
|
|
2013
Q4 | $60.4M | Sell |
1,183,729
-72,595
| -6% | -$3.64M | 0.17% | 136 |
|
|
2013
Q3 | $63.2M | Buy |
1,256,324
+78,149
| +7% | +$4.09M | 0.19% | 122 |
|
|
2013
Q2 | $57.9M | Buy |
+1,178,175
| New | +$64.1M | 0.18% | 122 |
|
Other funds holding LLY
Eaton Vance Management's LLY Position: Q3 2022 in Review
Eaton Vance Management reduced its Eli Lilly (LLY) stake by 5% in Q3 2022, selling an estimated $55.6M and leaving 3,333,022 shares worth $1.08B. The position accounts for 1.6% of the portfolio, ranked #5.
Eaton Vance Management first reported a position in LLY in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.14B in Q2 2022. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.
- Eaton Vance Management held 3,333,022 shares of Eli Lilly worth $1.08B as of Q3 2022.
- Eaton Vance Management sold 175,598 Eli Lilly shares in Q3 2022, an estimated $55.6M.
- Eli Lilly made up 1.6% of Eaton Vance Management's portfolio in Q3 2022, its #5 holding.
- Eaton Vance Management first reported a position in Eli Lilly in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Eli Lilly position peaked at $1.14B in Q2 2022.
- 2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.